Sentences with word «ozogamicin»

Common adverse events (AEs) associated with inotuzumab ozogamicin include abdominal pain, anemia, fatigue, febrile neutropenia, headache, hemorrhage, hyperbilirubinemia, infection, leukopenia, liver damage, nausea, neutropenia, pyrexia, and thrombocytopenia.

Inotuzumab ozogamicin includes a boxed warning due to the risk of severe hepatotoxicity, including sinusoidal obstruction syndrome or veno - occlusive disease (VOD).

Inotuzumab ozogamicin may cause harm to a fetus or newborn; as such, women who are pregnant or breastfeeding should not take the drug.

The rate of complete remission was higher in patients treated with inotuzumab ozogamicin compared with chemotherapy (81 % vs 29 %), as was the rate of minimal residual disease (MRD) negativity (78 % vs 28 % with chemotherapy) among those who achieved complete remission.

Median overall survival was higher in the inotuzumab ozogamicin arm (7.7 months vs 6.2 months) but these results did not reach statistical significance.

Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high - risk acute myeloid leukemia (AML), according to a study led by St. Jude Children's Research Hospital.

The US Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of relapsed or refractory B - cell precursor acute lymphoblastic leukemia (ALL) in the adult population.

Patients were randomized 1:1 to receive treatment with investigator's choice of chemotherapy or inotuzumab ozogamicin.

Hematopoietic stem cell transplantation was also more common in patients treated with inotuzumab ozogamicin (48 % vs 22 %).

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B - cell precursor acute lymphoblastic leukemia.